Warrick Brandon J, Tataru Anita Paula, Smolinske Susan
a New Mexico Poison and Drug Information Center, University of New Mexico , Albuquerque , NM , USA ;
b Faculty of Pharmaceutical Sciences , The University of British Columbia , Vancouver , Canada.
Clin Toxicol (Phila). 2016 Aug;54(7):547-55. doi: 10.1080/15563650.2016.1180390. Epub 2016 May 19.
Pharmacologically induced shock can be refractory to standard resuscitation. Methylene blue (MB) acts to prevent nitric oxide-mediated vasodilation and may be a potential treatment for refractory shock.
A systematic analysis of the literature to evaluate MB in pharmacologically induced shock. Primary outcome was survival and secondary outcome was hemodynamic improvement.
A search of MedLine/PubMed, EMBASE, Cochrane Library, TOXLINE, Google Scholar and Google was performed 10 August 2015 using a combination of text words and keywords related to MB, shock and specific drugs. We included primary literature articles reporting clinical outcomes in humans.
The searches yielded 928 citations, with 255 exact duplicates. Of the 673 entries screened, 16 citations met study criteria and comprised 17 cases. Calcium channel blockers (CCBs) represented ten cases (six amlodipine, two verapamil, and two diltiazem), atenolol three cases as coingestant with amlodipine, five metformin, one ibuprofen, and one multidrug (quetiapine, carbamazepine, valproic acid, oxazepam, and fluoxetine). Twelve patients survived and nine had hemodynamic improvement following MB administration. Four did not respond to MB but survived with other advanced resuscitative measures. None of the seven cases had BP improvement and four died when lipid was given prior to MB, compared to one death and nine cases of BP improvement when lipid was not given. In all cases, MB was used after failing several other treatments. Bolus doses ranging from 1 to 3 mg/kg, with repeat boluses or maintenance infusions. Reported adverse events were temporary self-limited blue discolorations.
While there are compelling cases describing an improved hemodynamic status following MB, there are also several cases without observed change. Currently, there is not enough evidence available to recommend the routine administration of MB in refractory pharmacologically induced shock.
药物性休克可能对标准复苏治疗无效。亚甲蓝(MB)可防止一氧化氮介导的血管舒张,可能是治疗难治性休克的一种潜在方法。
对文献进行系统分析,以评估MB在药物性休克中的作用。主要结局是生存,次要结局是血流动力学改善。
2015年8月10日,使用与MB、休克和特定药物相关的文本词和关键词组合,对MedLine/PubMed、EMBASE、Cochrane图书馆、TOXLINE、谷歌学术和谷歌进行了检索。我们纳入了报告人类临床结局的原始文献文章。
检索得到928条引文,其中255条为完全重复。在筛选的673条记录中,16条引文符合研究标准,包括17例病例。钙通道阻滞剂(CCB)占10例(氨氯地平6例、维拉帕米2例、地尔硫䓬2例),阿替洛尔3例为与氨氯地平同时摄入,二甲双胍5例,布洛芬1例,多药联合(喹硫平、卡马西平、丙戊酸、奥沙西泮和氟西汀)1例。12例患者在给予MB后存活,9例血流动力学改善。4例对MB无反应,但通过其他高级复苏措施存活。7例患者在MB前给予脂质时血压均未改善,4例死亡,而未给予脂质时1例死亡,9例血压改善。在所有病例中,MB均在其他几种治疗失败后使用。推注剂量为1至3mg/kg,可重复推注或维持输注。报告的不良事件为暂时性自限性皮肤发蓝。
虽然有令人信服的病例描述了MB治疗后血流动力学状态改善,但也有一些病例未见变化。目前,没有足够的证据推荐在难治性药物性休克中常规使用MB。